吉姆3缓冲和增强影响酵母菌可纳敏感性的新突变
Mohammed T Tawfeeq1,2, Dimitrios Konstantinidis1,2, Ana Lucia Rocha Iraizos1,2,3,4,5,6
1VIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.
EMBO reports
|February 17, 2026
概括
蛋白质折叠伴侣Gim3影响了新突变如何在抗真菌药物压力下影响酵母进化. 删除Gim3降低了药物易感性,这表明它是新的抗真菌疗法的潜在目标.
科学领域:
- 分子生物学分子生物学
- 进化生物学 进化生物学
- 菌类学 菌类学是指菌类学.
背景情况:
- 吉姆3是一种保存的蛋白质折叠伴侣,是前折叠蛋白复合体的一部分.
- 以前的研究表明,GIM3与酵母中的新突变相互作用,影响了它们的健康状况.
- 在对环境压力的反应中调节突变的进化影响中的Gim3的作用是未知的.
研究的目的:
- 调查Gim3在可纳应激下新突变的演变中的作用.
- 为了确定Gim3是否会影响真菌对抗真菌药物fluconazole的敏感性.
- 评估Gim3作为抗真菌药物耐药性的潜在治疗标.
主要方法:
- 在Saccharomyces cerevisiae的突变发生.
- 暴露于不同度的可纳在存在或不存在的GIM3.
- 评估真菌生长和突变的表型影响.
主要成果:
- 吉姆3通过允许突变表现出即时的表型效应来增强可纳的敏感性.
- 删除GIM3显著减少了大多数突变物在可纳压力下的真菌生长.
- 发现Gim3可以调节真菌病原体Nakaseomyces glabratus的可纳的敏感性.
结论:
- 吉姆3在塑造对抗真菌药物压力的进化反应方面发挥着至关重要的作用.
- 吉姆3增强了真菌对可纳的敏感性,表明其作为治疗点的潜力.
- 吉姆3在调节药物敏感性的功能在不同的真菌物种中得到保护.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:22Bioreactor Controls-III
67
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
67
01:15Antifungal Agents
119
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119